Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

<< Previous
Bullboard Posts
Post by Possibleidiot01on Jan 07, 2025 6:30am
38 Views
Post# 36391850

reporting threshold

reporting thresholdFax Capital now under.

FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.

GlobeNewswireJan 6, 2025 5:18 PM EST

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- This press release is being disseminated as required by National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the filing of an early warning report by FAX Capital Corp. ( FAX ) regarding the disposition of common shares ( Shares ) of BioSyent Inc. ( BioSyent ) (TSXV:RX) through the facilities of the TSX Venture Exchange.

FAX announces that, on January 6, 2025, it disposed of 122,910 Shares of BioSyent at an average price of $11.15 per Share and received aggregate consideration of $1,370,446.50 (the Disposition ). Immediately prior to the Disposition, FAX owned and controlled 1,205,700 Shares, representing 10.40% of the total number of issued and outstanding Shares of BioSyent. Following the Disposition, FAX now owns and controls 1,082,790 Shares, representing an aggregate securityholding percentage of 9.34%.

FAX currently has no plans or intentions with respect to its remaining Shares of BioSyent and such Shares will continue to be held for long-term investment purposes. In the future, FAX may acquire additional Shares, or dispose of its holdings, both as investment conditions warrant.

BioSyent is a publicly traded specialty pharmaceutical company which, through its wholly owned subsidiaries, BioSyent Pharma Inc. and BioSyent Pharma International Inc., sources, acquires or in-licences and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. The head office of BioSyent is located at 2476 Argentia Road Suite 402, Mississauga, Ontario, L5N 6M1.

A copy of the early warning report will be available under BioSyent’s profile on SEDAR+ at www.sedarplus.ca , or may be obtained by contacting Ryan Caughey, General Counsel and Corporate Secretary at (647) 696-4679. FAX is a corporation incorporated under the laws of Canada and its head office is located at 2 Bloor Street West, Suite 1000, Toronto, Ontario, M4W 3E2.

About FAX Capital Corp.

FAX is an investment company focused on the long-term asset management of high-quality investments within North America. FAX’s investment focus is the acquisition of a concentrated portfolio of public and private securities, with the flexibility to invest across the capital structure and in a wide variety of industries. www.faxcapitalcorp.com .

For additional information please contact:

Investor Relations - Email: IR@faxcapital.com

<< Previous
Bullboard Posts